Recently, Sichuan Kelun-Bestein Biopharmaceutical Co., Ltd. (Baili Tianheng) has been officially recognized by the Chengdu municipal government as a ‘Comprehensive Headquarters Enterprise.’ This designation not only reflects the government’s high recognition of the company’s comprehensive capabilities in R&D, manufacturing, commercialization, and global operations, but also reinforces Baili Tianheng’s leading position in the biopharmaceutical industry.The ‘Comprehensive Headquarters Enterprise’ status is a prestigious qualification established by Chengdu to support leading enterprises with global resource allocation, industrial chain integration, and innovation leadership capabilities. To qualify, companies must demonstrate excellence in technological originality, market influence, management standards, and sustainable development. Baili Tianheng distinguished itself through continuous breakthroughs in cutting-edge fields such as antibody-drug conjugates (ADCs) and bispecific antibodies, along with its robust R&D presence and commercialization capabilities spanning China, the United States, and Europe.As a high-tech enterprise focused on innovative biologics, Baili Tianheng has significantly increased its R&D investment in recent years, establishing a fully integrated global R&D system and advancing multiple novel drug candidates into late-stage clinical trials and toward commercialization. This new recognition is expected to bring substantial benefits in terms of policy support, resource access, and talent acquisition, accelerating the company’s international expansion and supporting the global reach of China-originated innovative medicines.
近日，百利天恒药业股份有限公司被成都市政府正式认定为‘全能型总部企业’。这一认定不仅体现了政府对其在研发、生产、销售及国际化布局等方面综合实力的高度认可，也标志着百利天恒在生物医药产业中的领先地位进一步巩固。‘全能型总部企业’是成都市为支持具有全球资源配置能力、产业链整合能力和创新引领能力的龙头企业而设立的重要资质。获得该认定的企业需在技术原创性、市场影响力、管理规范性和可持续发展等方面达到较高标准。百利天恒凭借其在抗体偶联药物（ADC）、双特异性抗体等前沿领域的持续突破，以及覆盖中国、美国、欧洲等多地的研发布局和商业化能力，成功脱颖而出。作为一家专注于创新生物药研发的高新技术企业，百利天恒近年来不断加大研发投入，构建了完整的全球化研发体系，并积极推进多个创新药物进入临床后期及上市阶段。此次获评‘全能型总部企业’，将为其在政策支持、资源对接、人才引进等方面带来显著优势，进一步加速其国际化战略进程，助力中国原创新药走向世界。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/9377.html